Tag Archives: ARNA

Top 10 Value Stocks To Invest In 2018

DryShips (DRYS) finally filed a 6-K after the close on July 25th that provided an update on its equity issuance for the period July 17th to July 25th. This was a break from prior disclosure patterns of providing updates on Fridays after the close or Mondays before the open as discussed in my article titled “Changing Its Disclosure Patterns?” The update on DRYS’ equity issuance was disappointing since the shares issued and the equity raised fell short of my expectations and, judging by the 20% losses in the stock into the late afternoon on July 26th, the market’s also. The following table summarizes the issuance for the period ending July 25th.

DryShips Equity Issuance Analysis Shares O/S July 7th (millions) 5.10 Funding Gap July 14th (millions) $5.56 Dates of Issuance July 17th – July 25th Shares Issued (millions) 14.08 Avg Issuance Price $1.88 July 25th Close $0.96 Shares O/S July 25th (millions) 19.18 Est of Value of Equity Issued $26.49

A close read of the 6-K reveals that most of the 14 million share issuance occurred July 21st through July 25th due to the pendency of the 1 for 7 reverse stock split announced on July 18th with an Effective Date of July 21st. The stock issued during this three day trading period equaled a bit more than 15% of the more than 91 million shares traded. Although this falls within the range of prior issuance percentages, it was a bit surprising that DRYS did not take advantage of the heavy trading volumes and price spikes and drive issuance closer to 20% of the shares traded. This resulted in lower equity proceeds than anticipated.

Top 10 Value Stocks To Invest In 2018: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Paul Ausick]

    Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.

  • [By Lisa Levin]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.

Top 10 Value Stocks To Invest In 2018: JA Solar Holdings, Co., Ltd.(JASO)

Advisors’ Opinion:

  • [By Monica Gerson]

    JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) is estimated to report its quarterly earnings at $0.68 per share on revenue of $683.29 million.

    Leju Holdings Ltd (ADR) (NYSE: LEJU) is projected to report its quarterly earnings at $0.14 per share on revenue of $194.20 million.

  • [By Travis Hoium]

    Earnings season is about over for the solar industry, and after JA Solar (NASDAQ:JASO) and Vivint Solar (NYSE:VSLR) reported this week, there were a few major takeaways from the end of 2016 and early 2017.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

Top 10 Value Stocks To Invest In 2018: (PIONF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    International Lithium (ILC) is a small lithium explorer/project generator with four joint venture lithium projects, and one fully-owned lithium project:

    Mariana lithium brine in Argentina (20% ILC: 80% GFL). ILC can increase to 30% via a 10% back-in right. Jiangxi Ganfeng Lithium (GFL) is committed to US$10m in expenditures at Mariana. This is their flagship project. Avalonia lithium pegmatite in Ireland (45% ILC: 55% GFL). GFL has the option to acquire an additional 24% after spending US$10m, or producing a Feasibility Study [FS]. Mavis Lake and Raleigh lithium pegmatite in Ontario Canada (49% ILC: 51% Pioneer Resources Limited (OTC:PIONF)). 100% of the Forgan Lake pegmatite project in Canada.

    Note that Avalon, Mavis Lake, Raleigh, and Forgan Lake also have rare earths. Jiangxi Ganfeng Lithium (SHE:002460) has an 18.1% stake in ILC in addition to the above joint venture partnerships.

Top 10 Value Stocks To Invest In 2018: ThyssenKrupp AG (TYEKF)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    In addition, the company announced that it has agreed to acquire a steel plant in Brazil from ThyssenKrupp (NASDAQOTH:TYEKF) for $1.3 billion. While that plant has had its share of problems in the past, Ternium is getting it for a good value, and it has upside potential. The company paid slightly less than five times EBITDA (earnings before interest, taxes, depreciation, and amortization) for the facility. As the following chart shows, that’s below the value that steel-company stocks trade for these days:

Top 10 Value Stocks To Invest In 2018: Royal Bank Scotland plc (The)(RBS)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

  • [By Jonathan Morgan]

    Adidas AG slid 2.9 percent after lowering its profit forecast for 2013. Direct Line Insurance Group Plc lost 2.5 percent as Royal Bank of Scotland Group Plc (RBS) sold a 630 million-pound ($1 billion) stake in the U.K.s biggest car insurer.

Top 10 Value Stocks To Invest In 2018: Barclays PLC(BCS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Barclays PLC (NYSE: BCS) was raised to Overweight from Equal Weight at Morgan Stanley. Its American depositary sharesclosed up 2.6% at $11.36 on Thursday and were indicated up 1.2% at $11.50 on Friday. The52-week range is $6.76 to $12.05.

  • [By WWW.THESTREET.COM]

    Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”

    ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”

Top 10 Value Stocks To Invest In 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Stavros Georgiadis]

    Gilead Sciences (NSDQ:GILD) has underperformed the market with its stock price down almost 25% compared to a 10.33% gain in Nasdaq Composite (INDX:COMPX) and 14.60% gain of Dow Jones Industrial Average (INDX:INDU). Gilead and Amgen (NSDQ:AMGN)have had a very tough year, so it is interesting to know if now is the time to invest in GILD stock, not from a bottom fishing point of investing, which is often too risky, but on some solid financial and fundamentals arguments.

  • [By Ben Levisohn]

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

  • [By Tom Gentile]

    After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.

Top 10 Value Stocks To Invest In 2018: Jacobs Engineering Group Inc.(JEC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Jacobs Engineering Group Inc. (NYSE: JEC) which rose about 9% to $64.92. The stocks 52-week range is $49.31 to $65.29. Volume was1.8 million compared to its average volume of less than 1 million.

  • [By Ben Levisohn]

    Lee offers 22 stocks that could benefit from the correlation trade: Western Digital (WDC), Xerox (XRX), First Solar, Ford Motor, Best Buy (BBY), PulteGroup (PHM), AutoNation (AN), Textron (TXT), Jacobs Engineering Group (JEC), Mosaic, BB&T (BBT), Fifth Third Bancorp (FITB),Loews (L), Regions Financial (RF), KeyCorp (KEY), Comerica (CMA), Leucadia National (LUK), Zions Bancorp (ZION), Valero Energy (VLO), Marathon Oil, Cardinal Health (CAH), and Pepco Holdings (POM).

Top 10 Value Stocks To Invest In 2018: Cytokinetics, Incorporated(CYTK)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to
  • [By Paul Ausick]

    Cytokinetics Inc. (NASDAQ: CYTK) dropped about 37% Tuesday to post a new 52-week low of $7.00 after closing at $11.10 on Monday. The 52-week high is $17.20. Volume was around 7 million, about 14 times the daily average of less than 500,000. The company’s ALS drug failed ti meet its endpoint in a phase 3 study.

  • [By Lisa Levin]

    Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 27 percent to $8.12 on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international Phase 3 study showed tiraemtive did not meet the primary endpoint of change from baseline in slow vital capacity, or SVS, evaluated at 24 weeks, as well the secondary endpoints evaluated at 48 weeks.

  • [By Chris Lange]

    Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesdays session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firms Phase 3 clinical trial of tirasemtiv did not meet the primary endpoint or any of the secondary endpoints.

Top 10 Value Stocks To Invest In 2018: Tenneco Inc.(TEN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of auto-part makers like Delphi Automotive (DLPH), BorgWarner (BWA), and Tenneco (TEN) are getting killed today, ostensibly due to an article in Automotive News. Wells Fargo’s Richard Kwas and team think Tesla Motors (TSLA) and its Model 3 deserve at least some of the blame:

stocks and bonds

"Oh man, I already missed out on the 'Melt Up.' I should have bought exciting tech companies like Facebook and Google a year ago. Now, it's too late…"   I hear that all the time. But – my friend – you're wrong…   You haven't missed the Melt Up – at all.   In the last year, Alphabet (GOOGL) – the parent company of Google – is up nearly 16%. Facebook (FB) is up around 33%.   Those are good returns, for sure. But they don't tell the full story…   The surprising truth is that over the last year, the boring, old-school companies of the Dow Jones Industrial Average have beaten the "hip" tech names in the Nasdaq Composite Index.   Take a look…  

Tech vs. Old School

stocks and bonds: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap obesity drug stock Arena Pharmaceuticals, Inc (NASDAQ: ARNA) is scheduled for after the market closes onTuesday (March 14th). Last June,Arena Pharmaceuticals announced a strategic shifting of priorities to emphasize its proprietary clinical stage pipeline and the implementation of additional cost reductions to streamline the organization to support its development programs. Among the actions to be taken is the layoff of 73% of the companys workforce which will cost approximately $6.1 million.

  • [By Paul Ausick]

    Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.

stocks and bonds: Enviva Partners, LP(EVA)

Advisors’ Opinion:

  • [By Manikandan Raman]

    There also some lesser known clean energy stocks that may witness downward movement on potential Trump win on negative sentiment. They include Pattern Energy Group Inc (NASDAQ: PEGI), Enviva Partners LP (NYSE: EVA), TerraForm Global Inc (NASDAQ: GLBL), Renewable Energy Group Inc (NASDAQ: REGI) and Ameresco Inc (NYSE: AMRC).

stocks and bonds: PetMed Express, Inc.(PETS)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) isstill below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been much stronger performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

  • [By Lisa Levin]

    Monday afternoon, the non-cyclical consumer goods & services shares surged 0.22 percent. Meanwhile, top gainers in the sector included Petmed Express Inc (NASDAQ: PETS), up 20 percent, and Kroger Co (NYSE: KR), up 3 percent.

  • [By Peter Graham]

    Small cap pet stockPetmed Express Inc (NASDAQ: PETS) reportedQ2 earnings before the market opened this morning with shares soaring this morning as earnings were well beyond expectations. Net sales increased 10% to $66.7 million as new order sales increased 9% to $11.6 million while the Company’s online sales for the quarter ended September 30, 2017 were approximately 84% of all sales compared to 82% for the same quarter the prior year (with online sales increasing 12%). Net income was $8.8 million versusnet income of $4.9 million. The CEO commented:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

stocks and bonds: Lucas Energy, Inc.(LEI)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    The Interior Department is in charge of managing regulations around oil and gas drilling around the nation. Currently, the favorite appears to be Forrest Lucas, the 74-year-old founder of Lucas Energy Inc. (NYSEMKT: LEI). A career energy executive, Lucas recently told Investors Business Daily that he would be interested in the job because “it’s a very important position and you need to have someone in there who knows what they’re doing.” However, Lucas has never actually met Trump in person.

stocks and bonds: Celanese Corporation(CE)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Albemarle Corporation (NYSE: ALB): Free Stock Analysis Report
     
    Celanese Corporation (NYSE: CE): Free Stock Analysis Report
     
    Kronos Worldwide Inc (NYSE: KRO): Free Stock Analysis Report
     
    Koppers Holdings Inc. (NYSE: KOP): Free Stock Analysis Report
     
    Chemours Company (The) (CC): Free Stock Analysis Report
     
    Kraton Corporation (NYSE: KRA): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Ben Levisohn]

    Time To Favor Optionality: Most macro data are similar to, or better than, when the merger was announced. As a result, the same returns have been obtainable, with significantly less stress, simply through owning 3M (MMM) or a basket of chemical companies that approximate the Dow-DuPont portfolio. Relative to the chemical sector, performance has been average, leverage appears reasonable but near-term FCF less-than compelling partly due to new capacity ramping. With the merger likely to close in the near-term (90% chance, in our view), we believe Dow-DuPont will have an opportunity to show how scale creates optionality. The overhaul at Celanese (CE) over the past few years shows the way.

stocks and bonds: Cleveland BioLabs, Inc.(CBLI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell by 0.98 percent. Meanwhile, top losers in the sector included Cleveland BioLabs, Inc. (NASDAQ: CBLI), down 25 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI), down 8 percent.

  • [By Alex McGuire]

    You see, penny stocks are attractive because they can offer double-digit or even triple-digit returns in a very short time. For example, Cleveland BioLabs Inc. (Nasdaq: CBLI) skyrocketed from $1.56 at the Thursday, April 13, close to $5.10 on Wednesday, April 19. That’s a stunning 227% return in just three sessions (the markets were closed that Friday).

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

penny stock finder

Which biotechs have high prospects of being acquired in the near future? Many would place Incyte (NASDAQ:INCY) near the top of the list. The company’s oncology portfolio makes it an attractive target.But a target for whom?

Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), and Amgen (NASDAQ:AMGN) stand out as three of the most likely suitors for Incyte. Here’s why these big drugmakers could be interested in making a significant acquisition.

Image source: Getty Images.

A perfect match

When industry observers were asked in 2016 which company they thought was most likely to buy Incyte, Gilead Sciences was the top answer. In some ways, Gilead and Incyte make an ideal match.

Investors are anxious for Gilead to make an acquisition to help plug the leak from its declining hepatitis C franchise sales. Gilead’s executives have also stated that a strategic deal ranks as one of their top priorities. The company’s CEO even identified strengthening Gilead’s oncology product lineup as a primary objective, but also mentioned augmenting its inflammation and non-alcoholic steatohepatitis (NASH) pipelines.

penny stock finder: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Paul Ausick]

    Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.

  • [By Keith Speights]

    Eisai partnered with Arena Pharmaceuticals (NASDAQ:ARNA) several years ago on obesity drug Belviq. The drug won U.S. regulatory approval in 2012, but sales have been underwhelming. As a result, Arena sold Belviq to Eisai earlier this year.

penny stock finder: Washington Trust Bancorp, Inc.(WASH)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

penny stock finder: Ollie's Bargain Outlet Holdings, Inc.(OLLI)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    All is not lost for retail, however. Cramer continued to recommend the closeout and discount chains like TJX Stores (TJX) , Ollie’s Bargain Outlet (OLLI) and Burlington Stores (BURL) . He was also bullish on those who cater to the millennials, like Six Flags (SIX) , Dave & Busters (PLAY) and Foot Locker (FL) , where trying on shoes never seems to go out of style.

  • [By Monica Gerson]

    Ollie’s Bargain Outlet Holdings Inc (NASDAQ: OLLI) is estimated to post its quarterly earnings at $0.17 per share on revenue of $190.44 million.

    MGC Diagnostics Corp (NASDAQ: MGCD) is projected to post earnings for the latest quarter.

penny stock finder: TransAlta Corporation(TAC)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell by 0.08 percent. Meanwhile, top losers in the sector included FirstEnergy Corp. (NYSE: FE), down 3 percent, and TransAlta Corporation (USA) (NYSE: TAC), down 2 percent.

  • [By Lisa Levin]

    In trading on Friday, utilities shares rose by just 0.5 percent. Meanwhile, top losers in the sector included TransAlta Corporation (USA) (NYSE: TAC), down 1 percent, and Huaneng Power International Inc (ADR) (NYSE: HNP), down 1 percent.

  • [By Lisa Levin]

    In trading on Monday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Companhia Paranaense de Energia (ADR) (NYSE: ELP), down 3.5 percent, and TransAlta Corporation (USA) (NYSE: TAC), down 5 percent.

penny stock finder: American Electric Power Company, Inc.(AEP)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Masco (MAS) , American Electric Power (AEP) and Valmont Industries (VMI) .

    Cramer was bearish on Wisconsin Energy (WEC) .

penny stock finder: EQT GP Holdings, LP(EQGP)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Not only does Jana consider the deal price overvalued, but it looks to redirect EQT’s focus to a breakup of pipeline operations to transform the core company into an exploration & production firm. The pipelines already trade publicly under EQT Midstream Partners LP (NYSE: EQM) and EQT GP Holdings LP (NYSE: EQGP).